To develop efficient therapies and identify novel early biomarkers for chronic kidney disease (CKD) an understanding of the molecular mechanisms orchestrating it is essential. We here set out to understand how differences in CKD origin are reflected in gene regulatory mechanisms.
Abstract
To develop efficient therapies and identify novel early biomarkers for chronic kidney disease (CKD) an understanding of the molecular mechanisms orchestrating it is essential. We here set out to understand how differences in CKD origin are reflected in gene regulatory mechanisms.
To this end, we collected and integrated publicly available human-kidney glomerular microarray gene expression data for nine kidney disease entities that account for a majority of CKD Rapidly progressive glomerulonephritis (RPGN)]. We included data from five distinct studies and compared glomerular gene expression profiles to that of non-tumor part of kidney cancer nephrectomy tissues. A major challenge was the integration of the data from different sources, platforms and conditions, that we mitigated with a bespoke stringent procedure. This allowed us to perform a global transcriptome-based delineation of different kidney disease entities, obtaining a landscape of their similarities and differences based on the genes that acquire a consistent differential expression between each kidney disease entity and tumor nephrectomy.
Furthermore, we derived functional insights by inferring signaling pathway and transcription factor activity from the collected gene expression data, and identified potential drug candidates based on expression signature matching. These results provide a foundation to comprehend the specific molecular mechanisms underlying different kidney disease entities, that can pave the way to identify biomarkers and potential therapeutic targets.
Introduction
Chronic Kidney Disease (CKD) is a major public health burden affecting around 10 % of the population in the western world. There is no specific therapy to slow down kidney functional decline and prevent progression to end-stage renal disease (ESRD) for the vast majority of kidney diseases. Thus patients face dialysis or kidney transplantation. However, mortality and morbidity on dialysis is high and transplant wait times number in years. Furthermore, dialysis patients consume dramatic proportions of healthcare budgets 1 . Despite of this, CKD/ESRD is not receiving as much attention as other diseases, and research-funding is much lower (e.g. infections, and toxins, among others, are also contributing to the prevalence of CKD the data presented here is focusing on the above mentioned diseases.
Regardless of the type of initial injury to the kidney the stereotypic response to chronic repetitive injury is scar formation and fibrosis with subsequent kidney functional decline. Scar forms in the tubulo-interstitium as tubulo-interstitial fibrosis and in the glomerulus referred to as glomerulosclerosis. Despite this stereotypic response that involves inflammation and expansion of scar secreting myofibroblasts the initiating stimuli are quite heterogeneous, ranging from an auto-immunological process in LN to poorly controlled blood glucose levels in DN. A better understanding of similarities and differences in the complex molecular process orchestrating disease initiation and progression will guide the development of novel targeted therapeutics.
A powerful tool to understand and model the molecular basis of diseases is the analysis of genome-wide gene expression data. This has been applied in the context of various kidney diseases contributing to CKD [3] [4] [5] [6] [7] , and most studies are available in the resource NephroSeq.
However, to the best of our knowledge, no study so far has combined these data sets to build a comprehensive landscape of the molecular alterations underlying different kidney diseases contributing to a majority of CKD prevalence. In this study, we set out to build such a data set.
We collected data from five large studies with gene expression data from kidney biopsies of patients of eight different glomerular disease entities leading to CKD (from now on CKD entities), FSGS, MCD, IgAN, LN, MGN, DN, HN and RPGN. We normalized the data with bespoke stringent procedures, which allowed us to study the similarities and differences among these entities in terms of deregulated genes, pathways, and transcription factors, as well as to identify drugs that revert their expression signatures and thereby might be useful to treat them.
Results

Assemble of a pan-CKD collection of gene expression profiles of patients
We searched in Nephroseq (www.nephroseq.org) and Gene Expression Omnibus (GEO) 8,9 and identified five available studies -GSE20602 10 ; GSE32591 11 ; GSE37460 11 ; GSE47183 12, 13 ; GSE50469 14 (see section 4.1.) -with human microarray gene expression data for nine different glomerular disease entities: FSGS, MCD, IgAN, LN, MGN, DN, HN and RPGN, as well as healthy tissue and non-tumor part of kidney cancer nephrectomy tissues as controls ( Figure 1A and B). In addition, for one dataset, patients were labeled as an overlap of FSGS and MCD (FSGS-MCD) and we left it as such. These studies were generated in two different microarray platforms. To be able to jointly analyze and compare the different CKD entities, we performed a stringent preprocessing and normalization procedure that involved quality control assessment, either cyclic loess normalization or YuGene transformation and a batch effect mitigation procedure (see Methods and Supplementary material), thus at the end we kept 6289 genes from 199 samples in total. From the two potential controls, healthy tissue and cancer nephrectomy, we chose the latter as reference for further analysis as the batch mitigation removed a large number of genes for the healthy tissue.
Technical heterogeneity across samples
We first examined the similarities among the samples to see the extent of potential batch effects. Data does not primarily cluster by study source or platform, which can be attributed to our batch mitigation procedure ( Figure 1C , Sup. Figure 1 ), but the technical heterogeneity of the samples is still present, most probably due to the batch-group imbalance (see section 4.4.
and Sup. Figure 1 ). Samples from RPGN and FSGS-MCD conditions seem to be more affected by platform-specific batch effects than samples from other conditions, most probably due to the unbalanced distribution of samples: RPGN and FSGS-MCD samples are exclusively represented in platform Affymetrix Human Genome U133 Plus 2.0 Array (GPL570). In addition both of these are the subjects of a singular study, so that the batch effect mitigation procedure was not feasible to be conducted on them. Thus, the relatively lower Spearman's correlation coefficients -0.6 vs. for the rest -could be attributed to this uneven sample distribution in microarray platforms. Spearman's correlation coefficients.
Biological heterogeneity of CKD entities
Keeping in mind the potential biases introduced by the technical heterogeneity, we set out to find molecular differences among glomerular CKD entities. For this purpose, we analyzed only the expression data obtained for glomeruli. First, we calculated the differential expression of individual genes between the different CKD entities and TN fitting linear models for microarray data 15, 16 . From the 6289 genes included in the integrated dataset, 1791 showed significant differential expression (|logFC| > 1, p-value < 0.05) in at least one CKD entity. RPGN was the CKD entity with the largest number of significantly differentially expressed genes (885), while MCD was the one with least (75). 12 genes showed significant differential expression across all the CKD entities (AGMAT, ALB, BHMT2, CALB1, CYP4A11, FOS, HAO2, HMGCS2, MT1F, MT1G, PCK1, SLC6A8). Interestingly, all these genes were underexpressed across all the CKD entities (none of them overexpressed for any CKD entity). In contrast, QKI and LYZ genes were significantly overexpressed in HN, IgAN, and LN, while significantly underexpressed in FSGS-MCD, and RPGN (and DN for QKI). 107 different genes were significantly differentially expressed in at least 6 CKD entities (Figure 2A ).
To better comprehend the divergence and the similitude of the CKD samples we applied diffusion maps, as an attempt to reveal the underpinning geometric structure of the glomerular CKD transcriptomics data ( Figure 2B ). Specifically, we asked how the distinct CKD entities localised with respect to each other based on a common set of differentially expressed genes with regard to the expression profile of tumor nephrectomy. Thus, the diffusion distance of a given CKD entity with regard to tumor nephrectomy implies the extent of expression profile divergence from that control.
The most distant condition from tumor nephrectomy is RPGN, which is arguably the most drastic kidney disease condition with the most rapid kidney functional decline among the 
Transcription factor activity in CKD entities
To further characterize the differences among the CKD entities, we performed various functional analyses. First, we assessed the activity of transcription factors (TFs; Figure 3 ), based the levels of expression of their known targets (see Methods). Changes in the target genes provides superior estimates of the TF activity than the expression level of the transcription factor itself 17, 18 (Figure 3 ). We found 10 TFs differentially regulated in at least one CKD entity ( Figure   3 ). Furthermore, we correlated the identified TF's activities with the expression of those genes, that are encoding for these TFs. The idea is that, while factors with negative correlation are potentially acting as repressors, whereas those with positive correlation are acting as activators.
Those with no correlation indicate factors whose activity is significantly modulated using posttranslational modifications or factors whose regulons or expression measurements are unconfident. For instance, Interferon regulatory factor-1 (IRF1) is significantly enriched in Lupus nephritis and moderately correlated (Spearman's rank-based correlation coefficient of 0.624) with the expression level of the gene encoding for IRF1. This suggests an as of yet undiscovered potential role of IRF1 as a transcriptional activator in Lupus nephritis. In addition, IRF1's transcriptional activity was elevated in LN with respect to the rest of the conditions. The activity of the upstream stimulatory factor 2 (USF2) -a basic helix-loop-helix (bHLH) TF 19 -is estimated to be significantly depleted in MCD compared to the rest of the conditions. Interestingly, USF2's estimated activity across the CKD entities is inversely correlated -Spearman's rho (r s = -0.867) -with the expression level of the gene USF2, that is encoding for the TF USF2. Intriguingly, USF2 has been implicated as a potential transcriptional modulator of Angiotensin II type 1 receptor (AT1R) -associated protein (ATRAP/Agtrap) in mice 19 .
Altogether, the identified TFs are estimated to exhibit different mode of action depending on the CKD entity. 
Signaling Pathway Analysis
We complemented the functional characterization of transcription factor activities with an estimation of pathways activities. For this, we applied two methodologies, our tool PROGENy 20 and a general gene set enrichment tool, Piano 21 .
Pathway activity of CKD entities using PROGENy
We first applied PROGENy, that infers pathway activity by looking at the changes in levels of the genes affected by perturbation on pathways. We have found that this provides a better proxy of pathway activity than looking at the genes in the actual pathway 20 . More specifically, whether it is expected to have a given PROGENy score for a particular pathway in a specific disease entity given the gene expression data at hand. Figure 
Pathway enrichment with Piano
While PROGENy can give accurate estimates of pathway activity, it is limited to 11 pathways for which robust signature could be generated 20 . To get a more global picture, we complemented that analysis with a gene-set-enrichment analysis using Piano 21 Figure 4B ). Figure 4B also shows that HN (52), MGN (45) , and IgAN (37) are the CKD entities with more pathways differentially enriched in at least 3 entities, result that agrees with Figure 2B showing these entities in the center of the diffusion map. 
Prediction of potential novel drugs indication to treat CKD
As a final analysis, we applied a signature-search-engine, L1000CDS 2 tool 22 . L1000CDS 2 measures the distance between two signatures of disease data and the LINCS-L1000 data, and then prioritizes small molecules that are expected to have reverse signature compared to disease signature. With L1000CDS 2 , we performed this analysis separately for the nine CKD entities and then identified 220 small molecules across the CKD entitles (Sup. Figure 5 ). In order to narrow down the list of 220 small molecules, we focused on 20 small molecules observed in the L1000CDS 2 output of at least 3 subtypes ( Figure 5A ). By manual curation of scientific publications, we found that four small molecules have experimental evidence to support their clinical relevance in CKD or renal disease animal model testing (Sup. Table 1 ). BRD-K04853698 (LDN-193189) which is known as a selective BMP signaling inhibitor, and has been shown to suppress endothelial damage in mice with chronic kidney disease 23 . Wortmannin is one of cell-permeable PI3K inhibitors, and it has been shown to decreases albuminuria and recovers podocyte damage for early diabetic nephropathy in rat 24 .
The tyrosine kinase inhibitor Nilotinib is a Food and Drug Administration (FDA) approved medication to treat chronic myelogenous leukemia (CML). 25 Iyoda et al. showed 26 To further explore the association of these drugs with CKD disease and progression, we analysed the expression data for the targets of the literature supported drug candidates. First, each drug candidate was mapped to genes that encode the proteins targeted by these drugs ( Figure 5B ). For each gene, its differential expression of any CKD entity against TN was evaluated. Out of the 11 mapped genes, MYLK3, a target of narciclasine, was significantly differentially expressed (under-expressed, logFC<-1, p<0.05) in two CKD entities (IgAN and LN) (Supplementary figure 6) . Complementarily, screened drugs were mapped to the pathways they affect based on their functional information. The enrichment of the subset of pathways was evaluated using the previous results from gene set analysis algorithm (piano). This time, only PI3KCI pathway appears to be both, significantly enriched for HN patient data (up-regulated, p<0.05), and as pathway affected by the candidate repositioned drugs (Wortmannin, PI3K inhibitor).
Discussion
In this paper, we have aimed to shed light on the commonalities and differences among glomerular transcriptomics of major kidney diseases contributing to the CKD epidemic affecting there are reports about minor albumin expression in the kidney 28 and thus decreased expression of the gene encoding for albumin (ALB) might be a negative feedback loop of cells exposed to high urinary albumin levels during progression of CKD. CALB1 encodes for calbindin 1 an intracellular calcium binding protein which has been reported to be downregulated in the rat UUO kidney-fibrosis model and the anti-glomerular basement membrane glomerulonephritis model 29 . Decreased urinary calbindin 1 was proposed as a biomarker for kidney injury 29 .
Other genes were specifically altered in certain kidney disease entities such as Quaking (QKI) or Lysozyme C (LYZ), significantly overexpressed/underexpressed/non-significant depending on the underlying kidney disease. It is known that QKI is associated with angiogenic growth factor release and plays a pathological role in the kidney 30 , while LYZ was known to be related with vascular damage and heart failure but was recently found to be increased in plasma during CKD progression 31 . This data supports the fact that despite a stereotypic response of the kidney to injury with glomerulosclerosis, interstitial fibrosis and nephron loss there are various disease specific differences that are important to understand in order to develop novel personalized therapeutics.
CKD is a complex disease with a high degree of polygenicity. Furthermore, it is a very heterogeneous condition that can be acquired through a variety of biological mechanisms which is reflected by the results of pathway analysis. There was little to no overlap in significantly enriched pathways between the different kidney disease entities. We found 59 different pathways that showed significant enrichment in at least 3 disease entities ( Figure 4B ), indicating that different disease entities share some general mechanisms but their underlying pathophysiology differs from one entity to another. Besides increasing the interpretability, the pathway analysis identify many more differences among disease-identities than the gene-level analysis (Figure 2A PROGENy ( Figure 4A ) estimated JAK-STAT, a major cytokine signal transduction regulator 32 , to be significantly activated in LN with respect to TN and DoROthEA (Figure 3 ) predicted the TFs IRF1 and STAT1 to be significantly enriched in LN. The estimated pathogenic influentiality of JAK-STAT/STAT1/Interferon signaling in LN is supported by various studies 33 34 35 .
We also used the signature-matching paradigm to explore potential drugs that could revert the disease phenotype, and found that four drugs could be an encouraging medicine for CKD entities. Even though more experimental validations are required for the unknown medical interaction between drugs of our results and CKD progression, our approach suggests that it is possible to find promising treatments for CKD with the concept of drug repositioning. In particular, for one of the identified drugs, nilotinib, results have already been confirmed that it is safe to use for treatment and there is supporting data of its value insight at indications for CKD 26 .
The analysis of the drug targets' expression found that MYLK3, a gene encoding for one of the targets of Narciclasine, was significantly underexpressed in IgAN and LN when compared with TN. Similarly, PI3KCI pathway, the target of Wortmannin was enriched in HN (up-regulated, p<0.05). This analysis attempts to refine the outcome of the repositioning analysis, and at the same time help to connect it to the disease mechanism both in gene as well as in pathway level.
We see our analysis as a first step towards a characterization of the similarities and differences of the various pathologies that lead to CKD. As more data sets become available, either microarray or RNA-seq, these can be integrated in our pipeline. Furthermore, the burgeoning field of single-cell RNA (scRNA) has started to produce data sets in kidney 36, 37 , which hold the potential to revolutionize our understanding of the functioning of the kidney and its pathologies 38 39 . In particular, scRNA data can provide us signatures of the many cell types of the kidney, which in turn can be used to deconvolute the composition of cell types 12 in the more abundant and cost-effective bulk expression datasets 39 . Other data sets, such as (phospho)proteomics 40 and metabolomics 41 , would complement gene expression towards a more complete picture of the CKD-entities. Ideally, all these data sets would be collected in a standardized manner to facilitate integration, which was a major hurdle in our study. Such a comprehensive analysis across large cohorts, akin to what has happened for the different tumour types thanks to initiatives such as the International Cancer Genome Consortium, can lead to major improvements in our understanding of and treatment venues for CKD 42 .
Methods
Data collection
Raw data CEL files of each microarray dataset -GSE20602 10 ; GSE32591 11 ; GSE37460 11 ; GSE47183 12, 13 ; GSE50469 14 -were downloaded and imported to R (R version 3.3.2) using the getGEOSuppFiles and read.affy function of the GEOquery and simpleaffy package, respectively 43 . Each dataset came from either Affymetrix Human Genome U133A Array or Affymetrix Human Genome U133 Plus2.0 array, therefore the preprocessing was done with the affy R package 44 accordingly.
Preprocessing and mapping
RNA quality was assessed by RNA degradation plots using the AffyRNAdeg function from the affy package. In order to assess the statistical characteristics of the raw data, the affyPLM package 45 was used and probe-level metric calculations were carried out on the CEL files by calling the fitPLM function. The homogeneity of probe sets was evaluated by Normalized Unscaled Standard Error (NUSE) and Relative Log Expression (RLE) boxplots [46] [47] [48] . We removed all arrays that showed greater spread of NUSE value distribution with respect to the rest or where the median NUSE value was above 1.05, as these features indicated the sign of low quality array. The RLE values represent the ratio between the expression of a probe set and the median expression of that probe set across all arrays in the data set. The ratios are expected to be centered around zero on a logarithmic scale. RLE boxplots were generated to visualise the distribution of RLE values. Array quality was evaluated by taking NUSE and RLE plots into account.
The preprocessing step also constituted background correction and log2 transformation of the raw values, of which was done by the Robust Multichip Average (RMA) package [49] [50] [51] .
Probe IDs were mapped to Entrez Gene ID resulting in 12437 (Platform GPL570, Affymetrix
Human Genome U133 Plus 2.0 Array) and 20514 (Platform GPL96, Affymetrix Human Genome U133A Array) unique Entrez gene identifiers, respectively. In the case where datasets contained multiple probes for the same Entrez ID gene, the probe with the highest interquartile range (IQR) was retained as the representative of that given gene in the dataset. For this filtering step, the nsFilter function from the genefilter package 52 was utilized.
Correlation of arrays
Correlation of arrays was assessed by hierarchical clustering of the arrays based on gene expression Spearman's rank-based correlation coefficients. Low Spearman correlation coefficients imply considerable differences between array intensities 53 .
Normalization and batch effect mitigation
When required, cyclic loess normalization was applied using the limma package 16, 54, 55 or
YuGene transformation was carried out using the YuGene R package 56 .
The efficient integration of the data from different sources and platforms requires batch effect management, which should be customised to the data at hand. The current data was heavily affected by platform-and study-specific batch effects, because the outcome categories (CKD entities and their samples) were unevenly distributed across the batches. The commonly used algorithms for correcting batch effects assume a balanced distribution of outcome categories across batches and are vulnerable to the group-batch imbalance [57] [58] [59] [60] . We conducted a stringent batch effect mitigation process in order to minimize the influence of technical heterogeneity.
First, we structured the data in a platform-specific manner. Then, we conducted differential gene expression analysis between those identical biological conditions that are originating from distinct study sources after cyclic loess normalization and removed those genes that are significantly differentially expressed between them, as it indicated difference mainly due to the data source, rather than the biological difference. We applied this procedure for the data fragments coming from Affymetrix Human Genome U133 Plus 2.0 Array and Affymetrix Human Genome U133A Array. Next, we merged the data sets between the two platforms using the overlapping genes, followed by a process to mitigate the platform-induced batch effect. This latter procedure is similar to the one used for the data source-specific batch effect mitigation.
By applying this stringent procedure, we eliminated the genes that are the most affected by batch effects. For the illustration of this procedure, see Sup. Figure 1 . The scater R package 61 was used for producing the batch effect management related plots.
Detection of genes with consistently small p-values across all studies
Based on the assumption that common mechanisms might contribute to all CKD entities we performed a Maximum p-value (maxP) method 62 -which uses the maximum p-value as the test statistic -on the output of the differential expression analysis of the hypothetically separate studies. The maxP test follows a beta distribution that is parametrized by α = K and β = 1 under the null hypothesis:
where θ k is the effect size of study k.
This hypothesis setting (symbolised by HS A ) aims to uncover differentially expressed (DE) genes that acquire non-zero effect sizes in all studies. To phrase it differently, it is designated to unravel DE genes that are characterised by a small p-value across all studies [62] [63] [64] .
To obtain the p-values, differential expression analysis was conducted on the batch effect mitigated data using the limma R package 15 . We contrasted each glomerular CKD entity with tumor nephrectomy condition -each CKD -tumor nephrectomy contrast represented a hypothetically separate "study" -and the lmFit function was used to fit a linear model to the expression data for each probe set in the array series, followed by the estimation of eBayes values and the execution of a moderated t-test by the empirical Bayes method for differential expression (eBayes function) 15, 53 .
Diffusion map
The batch mitigated data containing merely the maxP identified (section 4.5.) 1790 genes (FDR < 0.01) (Sup. file 1), were YuGene transformed 56 and the destiny R package 65 was utilised to produce the diffusion maps.
Functional Analysis
Transcription factor activity analysis
We estimated transcription factor activities in the glomerular CKD entities using DoRothEA 17 which is a pipeline that tries to estimate transcription factor activity via the expression level of its target genes utilizing a curated database of transcription factor -target gene interactions (TF Regulon). The cyclic loess normalized expression values of all genes in all conditions were scaled and re-centered across the conditions and the transcription factors activities were estimated from the TF Regulon using VIPER 18 . We then conducted a Spearman's rank-based correlation between the identified transcription factors' activity and the scaled and re-centered expression of the genes encoding for these transcription factors. Since as a consequence of the batch effect mitigation procedure we lost many potentially informative genes, the coverage of the TF regulon database was limited and hence our statistical power decrease, meaning that there might be more differentially regulated TFs.
Inferring Signaling Pathway Activity fusing PROGENy
We used the cyclic loess normalised and batch effect mitigated expression values for PROGENy 20 , a method which utilizes downstream gene expression changes due to pathway perturbation in order to infer the upstream signaling pathway activity. The expression values were standardised to express a distance of each CKD sample from tumor nephrectomy (CKD entity sample scaled by the standard deviation of tumor nephrectomy). We used the overlapping genes between the standardised gene expression matrix and the PROGENy model. Then, a matrix multiplication was done to get the product matrix, containing a PROGENy score for each pathway in each CKD entity. A positive PROGENy score in a given pathway in a given CKD entity implies higher signaling activity compared to that specific pathways' activity in tumor nephrectomy, and vice versa for a negative PROGENy score.
Statistical significance was assessed using permutation-based hypothesis testing. We resampled the standardised gene expression values in a way that results in the randomised allocation of expression values to different glomerular disease labels. This resampling was done ten thousand times. We then computed PROGENy scores from these permuted Z-scores, resulting in a list of glomerular CKD entity specific PROGENy scores. By applying this approach we generated an empirical null distribution on the basis of the original gene expression sample distribution. The probability that the original PROGENy score in a given glomerular CKD entity is coming from the estimated null distribution or not was evaluated in a pathway-specific manner. We used a p-value of 0.05 as the threshold for statistical significance.
Furthermore, we applied the Benjamini-Hochberg adjustment 66 
Drug repositioning
Cyclic loess normalized gene expression data for nine glomerular CKD entities were analyzed separately for measuring characteristic direction (CD) 67 . Cosine distance for each gene was computed to the line which has 90 degree to the hyperplane which set the given CKD entity apart from tumor nephrectomy in N-dimensional gene expression space. Then, for each CKD entity, the signature of cosine distances computed by characteristic direction was applied to a signature-search-engine, L1000CDS 2 22 with the mode of reverse in configuration. L1000CDS 2 provided the top 50 ranked small molecule candidates with 1-cos(a), p-value, drug database links. Significant small molecules with FDR < 0.05 were filtered in for the nine CKD entities, separately. For converting the name of small molecules into general chemical names, we referred to LINCS phase I, II dataset stored in GEO (GSE92742, GSE70138) 68 .
Supplementary material
Illustration of the batch effect mitigation procedure
For illustrative purposes the batch effect mitigation process will be illuminated using samples from the condition IgA Nephropathy (IgAN). IgAN samples are only represented in platform Affymetrix Human Genome U133A Array (GPL96), however, these samples are originating from two distinct studies, GSE37460 11 and GSE50469 14 , respectively. Sup. Figure 1A dissimilarity. We conducted differential expression analysis using limma 15 between the IgAN samples of GSE37460 and that of GSE50469. Sup. Figure 1B shows an MA plot that visualises the difference in gene expression between the GSE37460 and GSE50469 IgAN samples.
Assuming that these two set of IgAN samples are essentially represent the same condition, the genes that are differentially expressed in this comparison are the ones that are the most affected by the platform-specific batch effect. Next, we started to remove the genes that are most affected by the batch effects. Sup. Figure 1C visualises Principal component 2 from Supp. measurements between the two studies seem to be closer to each other than before the procedure. Sup. Figure 1E shows for each gene the variance that is explained by group (CKD entity), study and platform, respectively, after batch effect mitigation. Most genes' variance is explained by group (CKD entity), however, there are genes for which the the variance in expression levels is largely attributed to platform or study. Even though this procedure does not completely eliminate or correct for the batch effects, we could show ,through this example, that we could mitigate the batch effects and gained some confidence that most genes' variance in expression between the samples are due to difference in disease. Figure 3 . Heatmap depicting the expression of the genes encoding for the transcription factors shown in Figure 4 . The expression values were averaged within each condition, then scaled and centered across the conditions. The numbers to the right of factor names are Spearman's rank-based correlation coefficients of factor activity and factor expression across different CKD entities.
